SURROZEN INC

SRZNNASDAQ

🏆 #3033 by market capEarnings Nov 6US Equity

$25.05▼ $0.04 (−0.16%)

🌙 After hours$25.05▲ 0.00%Regular close · extended-hours price shown

1h—

24h▼ 0.2%

7d▲ 14.1%

14d▲ 30.1%

30d▲ 10.2%

1y▲ 150.9%

🏦Market Cap

$187M

Small Cap

📈Revenue Growth (YoY)

-67.4%

Declining

📊Gross Margin

99.4%

High

💵FCF Margin

-413.5%

Thin

⚖️P/S Ratio

16.3x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $24.74 – $25.42
52-Week Range: $9.66 – $35.00
Volume: $2.60B
Avg Volume: $1.90B
Shares Outstanding: 7.5M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $5M
P/E Ratio: -0.6
P/S Ratio: 16.3x
EPS (TTM): $-28.48
Dividend Yield: 0.00%

Why Investors Own SRZN

✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
✓Healthy economics — 80% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▲ +47.5% YoY

Gross Margin (TTM)

79.9%▲ +3.5% YoY

Operating Income (TTM)

$403,332▲ +47.5% YoY

Free Cash Flow (TTM)

$392,901▲ +47.5% YoY

About SURROZEN INC

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

🦦